Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherHighlighted Papers

Epigenectic Regulation of Angiomyogenesis to Preserve Myocardial Performance

Journal of Pharmacology and Experimental Therapeutics April 2012, 341 (1) 1;
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Inhibition of histone deacetylases (HDACs) by trichostatin A (TSA) has previously been shown to induce a pharmacological preconditioning effect against acute myocardial ischemia and reperfusion injury; however, it is not clear whether the mechanism of TSA promotes endogenous angiomyogenesis in infarcted mouse hearts. In the present study, Zhang et al. investigated whether in vivo inhibition of HDAC preserves cardiac performance and prevents cardiac remodeling in mouse myocardial infarction (MI) through stimulation of endogenous regeneration. These studies demonstrate that in vivo inhibition of HDAC improved cardiac functional recovery and antagonized myocardial remodeling in chronic MI. Notably, HDAC inhibition significantly improved animal survival rate after MI, which is associated with the mitigation of both myocardial and serum tumor necrosis factor α levels in MI heart. HDAC inhibition stimulated the self-renewal of cardiac stem cells and resulted in robust increases in proliferation and cytokinesis in the MI hearts, which are associated with the enhancement of the newly formed myocytes and angiogenic responses. HDAC inhibition-induced cardioprotection also involves the activation of Akt-1 and inhibition of apoptosis. This study provides novel evidence that a new therapeutic strategy could be developed based upon HDAC inhibition, eliciting the stimulation of cardiac endogenous regeneration and angiogenesis in the infarcted heart.

See article at J Pharmacol Exp Ther 2012, 341:285–293.

  • Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 341 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 341, Issue 1
1 Apr 2012
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Epigenectic Regulation of Angiomyogenesis to Preserve Myocardial Performance
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherHighlighted Papers

Epigenectic Regulation of Angiomyogenesis to Preserve Myocardial Performance

Journal of Pharmacology and Experimental Therapeutics April 1, 2012, 341 (1) 1;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherHighlighted Papers

Epigenectic Regulation of Angiomyogenesis to Preserve Myocardial Performance

Journal of Pharmacology and Experimental Therapeutics April 1, 2012, 341 (1) 1;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Directly Observable Behavioral Effects of Lorcaserin in Rats
  • Magnesium Modifies the Impact of Calcitriol Treatment In Chronic Kidney Disease
  • Minimal Anticipated Biological Effect Level of Anti-CD28 Receptor Antagonist
Show more Highlighted Papers

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics